The New Reticulocyte Parameter (RET-Y) of the Sysmex XE 2100: Its Use in the Diagnosis and Monitoring of Posttreatment Sideropenic Anemia

Mauro Buttarello, Valeria Temporin, Renato Ceravolo, Giorgio Farina, Pietro Bulian

Research output: Contribution to journalArticle

54 Citations (Scopus)

Abstract

To verify their clinical usefulness in diagnosis and early response to therapy of sideropenic anemia, we compared the behavior of the reticulocyte parameter (RET-Y), a raw measure dependent on size and content of the cell, generated by the Sysmex XE 2100, with the mean reticulocyte volume (MCVr) and mean reticulocyte hemoglobin content (CHr) from the Bayer ADVIA 120 in healthy subjects and patients with iron deficiency anemia. Correlations were high (r = 0.88 and r = 0.94, respectively). All parameters varied significantly as early as 48 hours after the start of intravenous iron therapy (mean differences of 17.4% [RET-Y], 4.5% [MCVr], and 9.5% [CHr]). Sudden decreases in those parameters at interruption of therapy indicate the reappearance of sideropenic erythropoiesis. The receiver operating characteristic curve demonstrated a high degree of efficiency in differentiating moderate or severe iron deficiency anemia from the healthy state. The best association between sensitivity and specificity was at a cutoff of channel 1,624 for RET-Y and 104.5 fL for MCVr (negative and positive predictive values, respectively, of 99.6% and 96.5% for RET-Y and 98.7% and 93.3% for MCVr). RET-Y is correlated closely with CHr and is useful for diagnosis and early monitoring after the administration of intravenous iron.

Original languageEnglish
Pages (from-to)489-495
Number of pages7
JournalAmerican Journal of Clinical Pathology
Volume121
Issue number4
DOIs
Publication statusPublished - Apr 2004

Fingerprint

Reticulocytes
Anemia
Iron-Deficiency Anemias
Iron
Erythropoiesis
Cell Size
ROC Curve
Intravenous Administration
Healthy Volunteers
Hemoglobins
Therapeutics
Sensitivity and Specificity

Keywords

  • Hematology analyzer
  • Iron deficiency anemia
  • Mean reticulocyte hemoglobin content
  • Mean reticulocyte volume
  • Reticulocyte parameters

ASJC Scopus subject areas

  • Pathology and Forensic Medicine

Cite this

The New Reticulocyte Parameter (RET-Y) of the Sysmex XE 2100 : Its Use in the Diagnosis and Monitoring of Posttreatment Sideropenic Anemia. / Buttarello, Mauro; Temporin, Valeria; Ceravolo, Renato; Farina, Giorgio; Bulian, Pietro.

In: American Journal of Clinical Pathology, Vol. 121, No. 4, 04.2004, p. 489-495.

Research output: Contribution to journalArticle

@article{c72cd5c397704452a90e26d9c2cb65c9,
title = "The New Reticulocyte Parameter (RET-Y) of the Sysmex XE 2100: Its Use in the Diagnosis and Monitoring of Posttreatment Sideropenic Anemia",
abstract = "To verify their clinical usefulness in diagnosis and early response to therapy of sideropenic anemia, we compared the behavior of the reticulocyte parameter (RET-Y), a raw measure dependent on size and content of the cell, generated by the Sysmex XE 2100, with the mean reticulocyte volume (MCVr) and mean reticulocyte hemoglobin content (CHr) from the Bayer ADVIA 120 in healthy subjects and patients with iron deficiency anemia. Correlations were high (r = 0.88 and r = 0.94, respectively). All parameters varied significantly as early as 48 hours after the start of intravenous iron therapy (mean differences of 17.4{\%} [RET-Y], 4.5{\%} [MCVr], and 9.5{\%} [CHr]). Sudden decreases in those parameters at interruption of therapy indicate the reappearance of sideropenic erythropoiesis. The receiver operating characteristic curve demonstrated a high degree of efficiency in differentiating moderate or severe iron deficiency anemia from the healthy state. The best association between sensitivity and specificity was at a cutoff of channel 1,624 for RET-Y and 104.5 fL for MCVr (negative and positive predictive values, respectively, of 99.6{\%} and 96.5{\%} for RET-Y and 98.7{\%} and 93.3{\%} for MCVr). RET-Y is correlated closely with CHr and is useful for diagnosis and early monitoring after the administration of intravenous iron.",
keywords = "Hematology analyzer, Iron deficiency anemia, Mean reticulocyte hemoglobin content, Mean reticulocyte volume, Reticulocyte parameters",
author = "Mauro Buttarello and Valeria Temporin and Renato Ceravolo and Giorgio Farina and Pietro Bulian",
year = "2004",
month = "4",
doi = "10.1309/W652-95DT-UWK7-U1HH",
language = "English",
volume = "121",
pages = "489--495",
journal = "American Journal of Clinical Pathology",
issn = "0002-9173",
publisher = "American Society of Clinical Pathologists",
number = "4",

}

TY - JOUR

T1 - The New Reticulocyte Parameter (RET-Y) of the Sysmex XE 2100

T2 - Its Use in the Diagnosis and Monitoring of Posttreatment Sideropenic Anemia

AU - Buttarello, Mauro

AU - Temporin, Valeria

AU - Ceravolo, Renato

AU - Farina, Giorgio

AU - Bulian, Pietro

PY - 2004/4

Y1 - 2004/4

N2 - To verify their clinical usefulness in diagnosis and early response to therapy of sideropenic anemia, we compared the behavior of the reticulocyte parameter (RET-Y), a raw measure dependent on size and content of the cell, generated by the Sysmex XE 2100, with the mean reticulocyte volume (MCVr) and mean reticulocyte hemoglobin content (CHr) from the Bayer ADVIA 120 in healthy subjects and patients with iron deficiency anemia. Correlations were high (r = 0.88 and r = 0.94, respectively). All parameters varied significantly as early as 48 hours after the start of intravenous iron therapy (mean differences of 17.4% [RET-Y], 4.5% [MCVr], and 9.5% [CHr]). Sudden decreases in those parameters at interruption of therapy indicate the reappearance of sideropenic erythropoiesis. The receiver operating characteristic curve demonstrated a high degree of efficiency in differentiating moderate or severe iron deficiency anemia from the healthy state. The best association between sensitivity and specificity was at a cutoff of channel 1,624 for RET-Y and 104.5 fL for MCVr (negative and positive predictive values, respectively, of 99.6% and 96.5% for RET-Y and 98.7% and 93.3% for MCVr). RET-Y is correlated closely with CHr and is useful for diagnosis and early monitoring after the administration of intravenous iron.

AB - To verify their clinical usefulness in diagnosis and early response to therapy of sideropenic anemia, we compared the behavior of the reticulocyte parameter (RET-Y), a raw measure dependent on size and content of the cell, generated by the Sysmex XE 2100, with the mean reticulocyte volume (MCVr) and mean reticulocyte hemoglobin content (CHr) from the Bayer ADVIA 120 in healthy subjects and patients with iron deficiency anemia. Correlations were high (r = 0.88 and r = 0.94, respectively). All parameters varied significantly as early as 48 hours after the start of intravenous iron therapy (mean differences of 17.4% [RET-Y], 4.5% [MCVr], and 9.5% [CHr]). Sudden decreases in those parameters at interruption of therapy indicate the reappearance of sideropenic erythropoiesis. The receiver operating characteristic curve demonstrated a high degree of efficiency in differentiating moderate or severe iron deficiency anemia from the healthy state. The best association between sensitivity and specificity was at a cutoff of channel 1,624 for RET-Y and 104.5 fL for MCVr (negative and positive predictive values, respectively, of 99.6% and 96.5% for RET-Y and 98.7% and 93.3% for MCVr). RET-Y is correlated closely with CHr and is useful for diagnosis and early monitoring after the administration of intravenous iron.

KW - Hematology analyzer

KW - Iron deficiency anemia

KW - Mean reticulocyte hemoglobin content

KW - Mean reticulocyte volume

KW - Reticulocyte parameters

UR - http://www.scopus.com/inward/record.url?scp=1642299543&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=1642299543&partnerID=8YFLogxK

U2 - 10.1309/W652-95DT-UWK7-U1HH

DO - 10.1309/W652-95DT-UWK7-U1HH

M3 - Article

C2 - 15080300

AN - SCOPUS:1642299543

VL - 121

SP - 489

EP - 495

JO - American Journal of Clinical Pathology

JF - American Journal of Clinical Pathology

SN - 0002-9173

IS - 4

ER -